NASDAQ · BCDA
BioCardia, Inc.
$0.93-$0.02 (-2.26%)
BioCardia, Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.56% below the high.
Loading market information…
NASDAQ · PFSA · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Profusa, Inc. Common Stock’s quoted price sits in the lower half of its reported 52-week range, 99.96% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Profusa, Inc. Common Stock’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Profusa, Inc., a digital health technology company, develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. It offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery. The company researches and develops the Lumee Glucose Platform which is designed to monitor glucose levels in interstitial fluid. Profusa, Inc. is based in Berkeley, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:55 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.93-$0.02 (-2.26%)
BioCardia, Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.56% below the high.
$0.93+$0.05 (+5.09%)
Biofrontera Inc.’s quoted price sits in the lower half of its reported 52-week range, 43.89% below the high.
$5.05+$1.34 (+36.12%)
Adial Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 45.41% below the high.
$1.86+$0.03 (+1.64%)
Check-Cap Ltd.’s quoted price sits in the upper half of its reported 52-week range, 40.58% below the high.
$0.83-$0.03 (-3.43%)
Lucyd, Inc’s quoted price sits in the lower half of its reported 52-week range, 58.89% below the high.
$3.33+$0.22 (+7.07%)
Sunshine Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.28% below the high.
$0.49-$0.04 (-8.22%)
Aprea Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.87% below the high.
$1.07$0.00 (0.0%)
Acurx Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 85.81% below the high.
